^
Association details:
| Biomarker: | IDH1 R132C + EGFR L861Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
Published date:
01/12/2021
Excerpt:
Patient 1 with IDH1_R132C and EGFR_L861Q had experienced disease progression after only 3.4 months (PFS) of gefitinib and then died in 3.6 months(OS: 7 months)...Activating IDH mutations have been associated with short PFS and short OS...
